SERAXIS Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.

SERAXIS Inc., a privately held regenerative medicine company today announced the successful production of stem cell derived pancreatic cells capable of regulating blood glucose in rodent models of insulin dependent diabetes.